Profile of Reactive Estrogen Species in Women with EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC)

被引：0
|
作者：
Bodor, J. N. [1 ]
Krzizike, D. D. [1 ]
Vanderveer, L. [1 ]
Eidbo, S. [1 ]
Zawislak, C. L. [1 ]
Ross, E. A. [1 ]
Andrews, A. J. [2 ]
Edelman, M. J. [1 ]
Treat, J. [1 ]
Clapper, M. L. [1 ]
机构：
[1] Fox Chase Canc Ctr, Philadelphia, PA USA
[2] Univ North Carolina Wilmington, Wilmington, NC USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
EGFR; Reactive Catechols; Estrogen; Metabolism;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA13.04
引用
收藏
页码：S75 / S75
页数：1
相关论文
共 50 条
  • [31] Efficacy and safety of aumolertinib in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis: a single-center retrospective study
    Zhuang, Lulu
    Yin, Xiaoyan
    Liu, Xiaoli
    Liu, Defeng
    Wei, Zhonghui
    Chen, Yu
    Zhao, Kaikai
    Li, Yankang
    Yu, Jinming
    Meng, Xiangjiao
    JOURNAL OF NEURO-ONCOLOGY, 2025, : 461 - 470
  • [32] Osimertinib in Relapsed EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases: Results from the TREM-Study
    Eide, I. J.
    Helland, A.
    Borrisova, S.
    Ekman, S.
    Cicenas, S.
    Koivunen, J.
    Gronberg, B. H.
    Brustugun, O. T.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2139 - S2140
  • [33] Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC)
    O'Leary, Connor
    Gasper, Harry
    Sahin, Katherine B.
    Tang, Ming
    Kulasinghe, Arutha
    Adams, Mark N.
    Richard, Derek J.
    O'Byrne, Ken J.
    PHARMACEUTICALS, 2020, 13 (10) : 1 - 16
  • [34] Inhibition of non-small cell lung cancer (NSCLC) growth by a novel small molecular inhibitor of EGFR
    Li, Jinsong
    Deng, Huayun
    Hu, Meichun
    Fang, Yuanzhang
    Vaughn, Amanda
    Cai, Xiaopan
    Xu, Lequin
    Wan, Wei
    Li, Zhenxi
    Chen, Shijie
    Yang, Xinghai
    Wu, Song
    Xiao, Jianru
    ONCOTARGET, 2015, 6 (09) : 6749 - 6761
  • [35] Effect of Local Therapy on Survival in Oligometastatic Epidermal Growth Factor Receptor (EGFR) Mutated Non-Small Cell Lung Cancer (NSCLC)
    Soon, Y. Y.
    Lee, C. C.
    Koh, W. Y.
    Leong, C. N.
    Tey, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S356 - S356
  • [36] TP53 Co-Mutations in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Prognosis and Therapeutic Strategy for Cancer Therapy
    Liu, Surui
    Yu, Jin
    Zhang, Hui
    Liu, Jie
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [37] Genotyping Non-Small Cell Lung Cancer (NSCLC)
    Delia Campos-Parra, Alma
    Cruz-Rico, Graciela
    Arrieta, Oscar
    GACETA MEXICANA DE ONCOLOGIA, 2012, 11 (01): : 35 - 44
  • [38] The immune profile of EGFR-mutated non-small-cell lung cancer at disease onset and progression after tyrosine kinase inhibitors therapy
    Fumagalli, Caterina
    Guerini-Rocco, Elena
    Vacirca, Davide
    Passaro, Antonio
    de Marinis, Filippo
    Barberis, Massimo
    IMMUNOTHERAPY, 2018, 10 (12) : 1041 - 1045
  • [39] Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells
    Xiao-Ming Jiang
    Yu-Lian Xu
    Mu-Yang Huang
    Le-Le Zhang
    Min-Xia Su
    Xiuping Chen
    Jin-Jian Lu
    Acta Pharmacologica Sinica, 2017, 38 : 1512 - 1520
  • [40] Three Primary Tumors Including EGFR-mutated Non-Small Cell Lung Cancer as First Presentation in Patient With Li-Fraumeni Syndrome
    Gower, Arjan
    Kim, Jong
    Spector, Kellie
    Menashe, Daniella
    Vail, Eric
    Natale, Ronald
    CLINICAL LUNG CANCER, 2021, 22 (01) : E116 - E121
12345